PDL1-Based Nomogram May Be of Potential Clinical Utility for Predicting Survival Outcome in Stage III Breast Cancer

References

• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Mazurakova A, Koklesova L, Samec M, et al. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA J. 2022;13(2):315–334. doi:10.1007/s13167-022-00277-2.
   PubMed Web of Science ®Google Scholar
• Du XL, Song L. Breast cancer incidence trends in Asian women aged 20 or older as compared to other ethnic women in the United States from 2000 to 2018 by time period, age and tumor stage. Cancer Epidemiol. 2022;76:102076. doi:10.1016/j.canep.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang J, Li Q, et al. Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts. Oncotarget. 2017;8(27):44851–44859. doi:10.18632/oncotarget.15268
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Vaz-Luis I, Lin NU, Keating NL, et al. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: a Population-Based Study. Oncologist. 2017;22(4):386–393. doi:10.1634/thencologist
   PubMed Web of Science ®Google Scholar
• Ben-Dror J, Shalamov M, Sonnenblick A. The History of Early Breast Cancer Treatment. Genes. 2022;13(6):960. doi:10.3390/genes13060960.
   PubMed Web of Science ®Google Scholar
• Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021;397(10286):1750–1769. doi:10.1016/S0140-6736(20)32381-3.
   PubMed Web of Science ®Google Scholar
• Mangieri CW, Ruffo J, Chiba A, et al. Treatment and Outcomes of Women With Large Locally Advanced Breast Cancer. Am Surg. 2021;87(5):812–817. doi:10.1177/0003134820956335.
   PubMed Web of Science ®Google Scholar
• Badiu DC, Zgura A, Gales L, et al. Modulation of Immune System – strategy in the Treatment of Breast Cancer. In Vivo (Brooklyn). 2021;35(5):2889–2894. doi:10.21873/invivo.12578.
   Web of Science ®Google Scholar
• Sivaganesh V, Promi N, Maher S, et al. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. Int J Mol Sci. 2021;22(5):2433. doi:10.3390/ijms22052433.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186. doi:10.1016/S1470-2045(19)30026-9.
   PubMed Web of Science ®Google Scholar
• Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):586–597. doi:10.1200/JCO.21.01497.
   PubMed Web of Science ®Google Scholar
• Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021;384(23):2229–2240. doi:10.1056/NEJMra2034861.
   PubMed Web of Science ®Google Scholar
• Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523–533. doi:10.1182/blood.2019000847.
   PubMed Web of Science ®Google Scholar
• Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174–189. doi:10.1038/s41568-021-00431-4.
   PubMed Web of Science ®Google Scholar
• Pezeshki PS, Mahdavi Sharif P, Rezaei N. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opin Biol Ther. 2021;21(12):1575–1590. doi:10.1080/14712598.2021.1929919.
   PubMed Web of Science ®Google Scholar
• Kapinova A, Mazurakova A, Halasova E, et al. Underexplored reciprocity between genome-wide methylation status and long non-coding RNA expression reflected in breast cancer research: potential impacts for the disease management in the framework of 3P medicine. EPMA J. 2023;14(2):249–273. doi:10.1007/s13167-023-00323-7.
   PubMed Web of Science ®Google Scholar
• Liskova A, Samec M, Koklesova L, et al. Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J. 2021;12(2):155–176. doi:10.1007/s13167-021-00242-5.
   PubMed Web of Science ®Google Scholar
• Lima EOL, Silva MMD. Quality of life of women with locally advanced or metastatic breast cancer. Rev Gaucha Enferm. 2020;41:e20190292. doi:10.1590/1983-1447.
   PubMedGoogle Scholar
• Verret B, Sourisseau T, Stefanovska B, et al. The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. Cancer Res. 2020;80(15):3062–3069. doi:10.1158/0008-5472.CAN-19-3260.
   PubMed Web of Science ®Google Scholar
• Gou Q, Dong C, Xu H, et al. PDL1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955. doi:10.1038/s41419-020-03140-2.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Z, Li Y, et al. PD-1/PDL1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol. 2021;12:731798. doi:10.3389/fphar.2021.731798.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast Cancer Immunotherapy: facts and Hopes. Clin Cancer Res. 2018;24(3):511–520. doi:10.1158/1078-0432.CCR-16-3001.
   PubMed Web of Science ®Google Scholar
• Deng M, Li SH, Fu X, et al. Relationship between PDL1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int. 2021;21(1):371. doi:10.1186/s12935-021-02081-w.
   PubMed Web of Science ®Google Scholar
• Arak H, Aytekin A, Canoz O, et al. Prognostic and Predictive Significance of PDL1 Expression in Non-Small Cell Lung Cancer Patients: a Single-Center Experience. Turk Patoloji Derg. 2021;37(3):239–248. doi:10.5146/tjpath.2021.01545.
   PubMedGoogle Scholar
• Manson QF, Schrijver WAME, Ter Hoeve ND, et al. Frequent discordance in PD-1 and PDL1 expression between primary breast tumors and their matched distant metastases. Clin Exp Metastasis. 2019;36(1):29–37. doi:10.1007/s10585-018-9950-6.
   PubMed Web of Science ®Google Scholar
• Zong L, Sun Z, Mo S, et al. PDL1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer. Gynecol Oncol. 2021;162(3):631–637. doi:10.1016/j.ygyno.2021.07.009.
   PubMed Web of Science ®Google Scholar
• Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PDL1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. doi:10.1186/s40425-019-0770-2.
   PubMed Web of Science ®Google Scholar
• Tashireva LA, Muravyova DT, Popova NO, et al. Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PDL1 Therapy. Biochemistry (Mosc). 2021;86(11):1461–1468. doi:10.1134/S0006297921110092.
   PubMed Web of Science ®Google Scholar
• Zhou QH, Li KW, Chen X, et al. HHLA2 and PDL1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000157. doi:10.1136/jitc-2019-000157.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Perrot D, et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology. 2017;6(3):e1278100. doi:10.1080/2162402X.2016.1278100.
   PubMed Web of Science ®Google Scholar
• Rrapaj E, Giacometti L, Spina P, et al. Programmed cell death 1 ligand 1 (PDL1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. Pathology. 2021;53(4):462–469. doi:10.1016/j.pathol.2020.09.018.
   PubMed Web of Science ®Google Scholar
• Billon E, Finetti P, Bertucci A, et al. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology. 2019;8(11):e1655362. doi:10.1080/2162402X.2019.1655362.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Ignatova D, Jedamzik J, et al. PDL1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018;7(6):e1435226.
   PubMed Web of Science ®Google Scholar
• Hou Y, Nitta H, Wei L, et al. PDL1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J. 2018;24(6):911–919. doi:10.1111/tbj.13112.
   PubMed Web of Science ®Google Scholar
• Parvathareddy SK, Siraj AK, Ahmed SO, et al. PDL1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. Cells. 2021;10(2):229. doi:10.3390/cells10020229.
   PubMed Web of Science ®Google Scholar
• Hou J, Zhao R, Xia W, et al. PDL1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–1275. doi:10.1038/s41556-020-0575-z.
   PubMed Web of Science ®Google Scholar
• Sobral-Leite M, Van de Vijver K, Michaut M, et al. Assessment of PDL1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018;7(12):e1509820. doi:10.1080/2162402X.2018.1509820.
   PubMed Web of Science ®Google Scholar
• Chao X, Liu L, Sun P, et al. Immune parameters associated with survival in metaplastic breast cancer. Breast Cancer Res. 2020;22(1):92. doi:10.1186/s13058-020-01330-6.
   PubMed Web of Science ®Google Scholar
• Chen L, Huang S, Liu Q, et al. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy. Front Immunol. 2022;13:849468.
   PubMedGoogle Scholar
• Gupta A, Chandra S, Chauhan N, et al. Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma. J Lab Physicians. 2022;14(4):491–496. doi:10.1055/s-0042-1757232.
   PubMedGoogle Scholar